LatchBio
LatchBio provides a modular, programmable data platform that accelerates biotech and biopharma R&D by centralizing biological data and computation. Their product suite includes Latch Data for scalable storage, Latch Registry for harmonized metadata, Latch Workflow Manager for orchestrating Nextflow and Snakemake pipelines, and Latch Pods for on‑demand cloud compute with integrated Jupyter and RStudio notebooks. The platform supports core bioinformatics formats (FASTQ, BAM, VCF, PDB) and developer tools and languages such as Python, R, Jupyter, Nextflow, and Snakemake, and integrates with major clouds (AWS, GCP, Azure) and common storage systems. LatchBio serves biotech R&D teams, solution providers, and research labs with a usage‑based pricing model that charges for compute and storage only.
LatchBio
LatchBio provides a modular, programmable data platform that accelerates biotech and biopharma R&D by centralizing biological data and computation. Their product suite includes Latch Data for scalable storage, Latch Registry for harmonized metadata, Latch Workflow Manager for orchestrating Nextflow and Snakemake pipelines, and Latch Pods for on‑demand cloud compute with integrated Jupyter and RStudio notebooks. The platform supports core bioinformatics formats (FASTQ, BAM, VCF, PDB) and developer tools and languages such as Python, R, Jupyter, Nextflow, and Snakemake, and integrates with major clouds (AWS, GCP, Azure) and common storage systems. LatchBio serves biotech R&D teams, solution providers, and research labs with a usage‑based pricing model that charges for compute and storage only.
TL;DR
What they do: Cloud-native data and compute platform for biological R&D (storage, analysis, visualizations, workflows, on-demand compute)
Founded: 2021
Founders / leadership: Alfredo Andere (CEO), Kenny Workman (CTO), Kyle Giffin (COO)
Funding: Raised a $28M Series A (Jun 2, 2022); total disclosed funding $33.2M
Customers / reach: Used to serve 300+ biopharmas and 40+ solution providers (reported)
Company Overview
Problem Domain
Biotech/biopharma R&D data infrastructure and compute for multiomics and sequencing workflows
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
28000000
Series A announced to expand the platform
Investor Signal
“Company lists multiple venture investors and prominent individual backers, including Coatue, Lux Capital, Haystack, Hummingbird Ventures, George Church, Jeff Dean, and Laura Deming.”